China
Han Kun Law Offices has advised and acted as PRC counsel to the underwriter in connection with the initial public offering of Yimutian Inc. ("Yimutian", NASDAQ: YMT) in the United States and listing on the Nasdaq Stock Market.Yimutian was established in 2014
China
On August 15, 2025, LegalOne, a global legal rankings organization, announced its "Deals of the Year – China 2024". Han Kun is featured in the rankings for 17 deals and tops the LegalOne Merits law firm rankings based on deal totals and rating
China
Recently, Han Kun was invited by The Legal 500, the world's leading legal directory, to author the China chapter for The Legal 500: Country Comparative Guides 2025: TMT (the "Guides"). The contributors include Kevin Duan (partner), Yuting Wang, Ziqian Zhang and Keyi Yang.Initiated by The Legal 500, the Guides aim to help readers understand core legal regulations and judicial practices in the field of technology law across different jurisdictions
China
Han Kun Law Offices LLP ("Han Kun Hong Kong") has provided English law and Hong Kong law legal services in connection with Peixian Urban Construction Investment Development Group Co., Ltd.'s ("Peixian Urban Construction Group") debut CNY2 billion 3-Year Bond issuance as Managers' and Trustee's international counsel.The coupon rate of the 3-Year Bonds is 3.70%. This deal is Peixian Urban Construction Group's debut issuance in the offshore bond market
China
On August 9, 2025, renowned legal directory LegalOne announced its "Greater Bay Area Special Awards 2025", which recognize lawyers, law firms, and in-house legal counsel that have demonstrated long-term commitment and outstanding performance in the GBA and reflect the professional landscape and growth potential of the region's legal services market
China
Recently, Han Kun was invited by The Legal 500, the world's leading legal directory, to author the China chapter of The Legal 500: Country Comparative Guides 2025: Artificial Intelligence (the "Guides"). The contributors include Kevin Duan (partner), Danmin Hong, Yaqi Li, and Yufeng Gan.Initiated by The Legal 500, the Guides systematically summarize legal issues related to artificial intelligence in China through a Q&A format
China
Managing Intellectual Property (MIP), a world-renowned IP publication, has recently announced its 2025 global IP STARS rankings. Han Kun was again recognized in the China domestic firm categories of "IP transactions (Tier 1)", "Patent disputes", "Trademark disputes", "Patent prosecution", and "Copyright" lists, owing to the firm's competitive IP division and exceptional service capabilities
China
Han Kun Law Offices is pleased to announce that Ms. Ruixin Jiang and Ms. Yi Xiong has have recently joined the firm. The addition of Ms. Jiang and Ms. Xiong will further strengthen and enhance Han Kun's trade compliance capabilities.Ms. Jiang has extensive experience in cross-border trade compliance, including import and export compliance management, trade planning and structuring, supply chain compliance, and export controls and sanctions.Ms
China
July 30, 2025 – RD Technologies announced the successful close of its Series A2 financing round, raising approximately US$40 million. This round attracted participation from a consortium of prominent investors, including China Harbour, Bright Venture, ZhongAn International, CMSC, and Hong Shan
China
Finalists have recently been announced in the ALB Hong Kong Law Awards 2025. Han Kun has been shortlisted for 12 award categories
China
On July 25, 2025, Inmagene Biopharmaceuticals successfully completed its reverse merger with Ikena Oncology, Inc. The combined entity has been officially renamed ImageneBio, Inc. ("Imagene") and was successfully listed on the Nasdaq Stock Market under the ticker symbol "IMA" on July 28, 2025.Imagene's core asset is IMG-007, a monoclonal antibody targeting OX40, which is currently undergoing a Phase 2b clinical trial for the treatment of moderate-to-severe atopic dermatitis
China
On July 28, 2025, GSK plc (LSE/NYSE: GSK) announced it has entered into agreements with Hengrui Pharma (600276.SH; 01276.HK) to develop up to 12 innovative medicines, adding significant new growth opportunities to the company beyond 2031. The programmes were selected to complement GSK's extensive Respiratory, Immunology & Inflammation (RI&I) and Oncology pipeline, and assessed for their potential best- or first-in class profiles
China
On July 24, 2025, LEGALBAND, a renowned legal directory, announced its "LEGALBAND 2025 China 30 Under 30" list, which highlights 30 stellar young lawyers in mainland China who possess outstanding professional abilities and are favored by clients. Han Kun lawyer Keke Zhou was named to the list.Reasons for being listed: Mr. Zhou focuses on the areas of private equity investment and financing, investment and mergers and acquisitions, etc
China
On July 23, 2025, China Business Law Journal (“CBLJ”) announced the winners of its 2025 China Business Law Awards. This year marks the fifth consecutive time for Han Kun to be presented the "Golden League" award, together with nine other elite PRC firms who are widely recognized for their overall competitiveness. Han Kun was also highlighted as a "Firm of the Year" in 13 practice areas/industry sectors
China
On July 22, 2025, renowned legal directory Legal Hall of Fame announced its "China Legal Pioneer List: Lawyers Recommended by Key Clients in 2025", focusing on legal elites who have truly won the trust of key clients, such as central government-owned enterprises, local state-owned enterprises, foreign-invested enterprises, and private enterprises
China
On July 21, 2025, Law.com International, a globally renowned legal directory, announced the finalists for the 2025 Asia Legal Awards, which recognize the most important transactions, the best law firms, and the most outstanding lawyers in Asia
China
On July 17, 2025, Asian Legal Business (ALB) announced the finalists for its ALB China Regional Law Awards 2025: East China, which is open to "local" law firms headquartered in Shandong, Jiangsu, Anhui, Zhejiang, Jiangxi, and Shanghai ("East China") and "non-local" law firms headquartered in other regions with branches/offices in East China. Han Kun has been nominated in the following 17 award categories, owing to the firm's outstanding practices in East China
China
In July 2025, Xgene Pharmaceutical Inc. and its affiliates ("Xgene Pharma") announced an exclusive licensing collaboration with Concord Acquisition (HK) Limited and its affiliates ("NeuroGen") for the XG005, an innovative non-opioid analgesic. Under the agreement, NeuroGen is granted exclusive rights of development, registration, manufacturing, and commercialization of XG005 in Chinese mainland, Hong Kong, and Macau
China
On 15 July 2025, Sino Biopharmaceutical Limited ("Sino Biopharm", 01177.HK) announced that its wholly owned subsidiary Chia Tai Pharmaceutical Investment (Beijing) Group Co., Ltd. (“Chia Tai Pharmaceutical”), LaNova Medicines Limited ("LaNova Medicines"), LaNova Medicines's shareholders, and other relevant parties entered into the Sale and Purchase Agreement
China
Han Kun Law Offices represented ChiNext-listed company Kidswant Children Products Co., Ltd. (301078.SZ) in successfully completing the acquisition of a related party's equity and jointly acquiring 100% equity in Siyu Industrial with the related party. The total transaction consideration was RMB 1.65 billion
China
Han Kun has served as the PRC legal counsel to Kanzhun Limited ("BOSS Zhipin", Stock Code: BZ.NADAQ, 02076.HK) in connection with the follow-on offering of its Class A ordinary shares.BOSS Zhipin is the leading online recruitment platform in China and was the first in China to adopt the direct recruitment model for the online recruitment industry
China
During its annual meeting in San Diego, California, the International Trademark Association (INTA) officially released its Annual Review of Chinese Case Law (2025). The report takes a bird's-eye view of milestone cases— ranging from prosecution to litigation, and cutting across bad-faith filing, imposed sanctions, and injunctive relief—and provides an insider analysis of the impact on the pace and shape of trademark rights protection in China
China
On March 14, 2025, Han Kun lawyer Aaron Gu was invited to be appointed as a member of the Digital & Intelligent Medical Ethics Review Panel under the Shanghai Ethics Committee for Clinical Research. Recently, the Review Panel held its first working meeting. Mr. Gu was invited to attend as a member and delivered a thematic presentation on "Overview of Ethics Review Systems and Key Issues in Medical Data Application"
China
TCL Technology Group Corporation ("TCL Technology") has recently secured a USD 200 million sustainability-linked offshore syndicated loan, marking the first of its kind in the domestic display panel industry. The facility was significantly oversubscribed—by more than three times—and attracted participation from 19 domestic and international banks
China
On July 3, 2025, renowned legal directory LEGALBAND announced its "2025 Client Choice: Top 15 Regional Stars", with the aim of presenting the top 15 most-favored “Regional Stars” in mainland China. Han Kun partner Ms. Li Zhang was named to the list.Reasons for selection: Ms. Zhang's practice areas include private equity and venture capital, mergers and acquisitions, overseas restructuring and listing, and foreign direct investment